These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8553775)

  • 41. A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.
    Sha J; Kirtley ML; Klages C; Erova TE; Telepnev M; Ponnusamy D; Fitts EC; Baze WB; Sivasubramani SK; Lawrence WS; Patrikeev I; Peel JE; Andersson JA; Kozlova EV; Tiner BL; Peterson JW; McWilliams D; Patel S; Rothe E; Motin VL; Chopra AK
    Clin Vaccine Immunol; 2016 Jul; 23(7):586-600. PubMed ID: 27170642
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
    Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
    PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of Yersinia pestis V antigen in attenuated salmonella typhimurium: development of a novel vaccine for plague.
    Leary SE; Eley SM; Williamson ED; Titball RW
    Contrib Microbiol Immunol; 1995; 13():216-7. PubMed ID: 8833838
    [No Abstract]   [Full Text] [Related]  

  • 44. An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague.
    Yamanaka H; Hoyt T; Bowen R; Yang X; Crist K; Golden S; Maddaloni M; Pascual DW
    Vaccine; 2009 Jan; 27(1):80-7. PubMed ID: 18955097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice.
    Anderson GW; Heath DG; Bolt CR; Welkos SL; Friedlander AM
    Am J Trop Med Hyg; 1998 Jun; 58(6):793-9. PubMed ID: 9660466
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell-mediated immune response to epitopic MAP (multiple antigen peptide) construct of LcrV antigen of Yersinia pestis in murine model.
    Shreewastav RK; Ali R; Uppada JB; Rao DN
    Cell Immunol; 2012; 278(1-2):55-62. PubMed ID: 23121976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Yersinia pestis (plague) vaccines.
    Titball RW; Williamson ED
    Expert Opin Biol Ther; 2004 Jun; 4(6):965-73. PubMed ID: 15174978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Experimental protective of fraction I of the plague microbe].
    Pautov VN; Chicherin IuV; Evstigneev VI; Byvalov AA; Kedrov OA
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Oct; (10):37-42. PubMed ID: 116458
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibodies and cytokines independently protect against pneumonic plague.
    Kummer LW; Szaba FM; Parent MA; Adamovicz JJ; Hill J; Johnson LL; Smiley ST
    Vaccine; 2008 Dec; 26(52):6901-7. PubMed ID: 18926869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V).
    Fellows P; Adamovicz J; Hartings J; Sherwood R; Mega W; Brasel T; Barr E; Holland L; Lin W; Rom A; Blackwelder W; Price J; Morris S; Snow D; Hart MK
    Vaccine; 2010 Nov; 28(49):7748-56. PubMed ID: 20920572
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The activity of NK and K cells in mice vaccinated against plague].
    Solokhin EV; Pchelintsev SIu; Iurov SV; Uraeva VI; Afanas'ev SS; Vorob'ev AA
    Zh Mikrobiol Epidemiol Immunobiol; 1994; (4):42-5. PubMed ID: 7992534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Construction of variants of Yersinia pestis EV76 (RIEG line) vaccine strain differing in antibiotic resistance spectra with stage-by-stage transduction of R-transposons].
    Cherniavskaia AS; Morozova IV; Lebedeva SA; Zarenkov MI
    Antibiot Khimioter; 2005; 50(7):13-7. PubMed ID: 16768208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plague vaccines and the molecular basis of immunity against Yersinia pestis.
    Quenee LE; Schneewind O
    Hum Vaccin; 2009 Dec; 5(12):817-23. PubMed ID: 19786842
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Immunologic activity of the "murine" toxin of the plague microbe in experiments on animals].
    Evstigneev VI; Chicherin IuV; Byvalov AA; Pautov VN; Dodonov NP
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Mar; (3):39-42. PubMed ID: 7245966
    [No Abstract]   [Full Text] [Related]  

  • 55. Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague.
    Garmory HS; Griffin KF; Brown KA; Titball RW
    Vaccine; 2003 Jun; 21(21-22):3051-7. PubMed ID: 12798649
    [TBL] [Abstract][Full Text] [Related]  

  • 56. One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults: An extended open-label study.
    Hu J; Jiao L; Hu Y; Chu K; Li J; Zhu F; Li T; Wu Z; Wei D; Meng F; Wang B
    Hum Vaccin Immunother; 2018; 14(11):2701-2705. PubMed ID: 29927704
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Yersinia pestis YscN ATPase mutant functions as a live attenuated vaccine against bubonic plague in mice.
    Bozue J; Cote CK; Webster W; Bassett A; Tobery S; Little S; Swietnicki W
    FEMS Microbiol Lett; 2012 Jul; 332(2):113-21. PubMed ID: 22537022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.
    Williamson ED; Packer PJ; Waters EL; Simpson AJ; Dyer D; Hartings J; Twenhafel N; Pitt ML
    Vaccine; 2011 Jun; 29(29-30):4771-7. PubMed ID: 21570437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin/F1/V, in healthy adult volunteers (DMID 08-0066).
    Frey SE; Lottenbach K; Graham I; Anderson E; Bajwa K; May RC; Mizel SB; Graff A; Belshe RB
    Vaccine; 2017 Dec; 35(48 Pt B):6759-6765. PubMed ID: 29037578
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis.
    Honko AN; Sriranganathan N; Lees CJ; Mizel SB
    Infect Immun; 2006 Feb; 74(2):1113-20. PubMed ID: 16428759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.